【US Stock Market Movement】Jazz Pharmaceuticals plunges on October 8: Target price lowered, insiders reduce holdings, and short-term pullback

Jazz Pharmaceuticals October 8th Sharp Decline Analysis

Keywords: Target price downgrade, insider selling, short-term pullback

1. On October 8, 2026, RBC Capital Markets lowered Jazz Pharmaceuticals’ target price from $299 to $296. Although the buy rating was maintained, this represents an adjustment in valuation expectations.

2. On October 1, 2026, a company director sold 6,000 shares of company stock worth approximately $1.382 million. After the disclosure, the director still held 345,875 ordinary shares.

3. As of October 8, 2026, the company had dropped a cumulative 7.86% over the past five days, with its share price falling back to its lowest level since May 5, 2026. There was no public information showing any new drug approvals, earnings, or unexpected regulatory negatives on that day.

(Disclaimer: This content was generated by AI technology summarizing publicly available information and is for reference only. It does not constitute investment advice.)